APOE4 carriership was predictive of membership to both AD biomarker groups (AD pathologic change: RR = 1.93, 95%CI 1.37–2.72, p < 0.001; AD pathology: RR 6.48, 95%CI 3.57–11.8, p < 0.001) but was not significantly different in the non-AD pathology group (RR = 1.27, 95%CI 0.83–1.93, p = 0.27), and AD/non-AD pathologic change group (RR = 1.09, 95%CI 0.50–2.36, p = 0.82) relative to the normal AD biomarker group. This evidence concerns the gene APOE and Alzheimer disease.